🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital25 Tianjin Medical University25 Tianjin Medical University General Hospital17
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Tianjin

940 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT05918133TNBC
DrugsPumitamig·Nab-paclitaxel
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Active, closed
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
NCT05382364Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
Pfizer
Phase 1
25
Harbin, Changsha, Changchun, Shanghai, Tianjin
2022-06-29
Active, closed
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
NCT05347225Hematological Malignancies
Merck Sharp & Dohme LLC
Phase 1
12
Guangzhou, Zhengzhou, Changsha, Tianjin
2022-06-09
Recruiting
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
NCT05366478Melanoma, Non Small Cell Lung Cancer, Cervical Carcinoma
DrugAutologous Tumor Infiltrating Lymphocytes
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 1
15
Tianjin
2022-05-30
Recruiting
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
NCT05430373Solid Tumors, Adult
Grit Biotechnology
Phase 1
31
Beijing, Chongqing, Shanghai, Chengdu, Tianjin
2022-05-23
Active, closed
Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia
NCT05356169Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
312
Tianjin
2022-05-19
Active, closed
GVM±R in Patients With Relapsed or Refractory Aggressive NHL
NCT05299164Non Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
18
Tianjin
2022-05-15
Recruiting
Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
NCT04631770Lung Neoplasms, Lymph Node Excision
Tianjin Medical University Cancer Institute and Hospital
Not applicable
1,362
Tianjin
2022-05-01
Recruiting
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
NCT05294055Multiple Myeloma, Lymphoma
DrugsEtoposide·Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Active, closed
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT05171647Non-Hodgkin Lymphoma
DrugsMosunetuzumab·Polatuzumab Vedotin·Tocilizumab·Rituximab
Hoffmann-La Roche
Phase 3
208
Chengdu, Fuzhou, Guangzhou, Tianjin, Wuhan, Zhengzhou
2022-04-25
Recruiting
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
NCT05145361NMO Spectrum Disorder
DrugB001
Shanghai Pharmaceuticals Holding Co., Ltd
Phase EARLY_PHASE1
45
Beijing, Taiyuan, Xi’an, Tianjin
2022-04-07
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT05239741Colorectal Neoplasms
DrugsLeucovorin·Irinotecan·Oxaliplatin·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
100
Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin
2022-04-02
Recruiting
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467Pulmonary Arterial Hypertension
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Guangzhou, Nanjing, Tianjin, Beijing, Changsha, Chendu, Shenyang, Wuhan
2022-03-29
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
DrugsElranatamab·Lenalidomide
Pfizer
Phase 3
854
Guangzhou, Tianjin, Wenzhou
2022-03-25
Recruiting
A Study of SKB315 in Patients With Advanced Solid Tumors
NCT05367635Advanced Solid Tumors
DrugSKB315
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
246
Tianjin
2022-03-16
Recruiting
Herombopag for Chemotherapy-induced Thrombocytopenia
NCT05236582Chemotherapy-induced Thrombocytopenia, Herombopag
DrugHerombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2022-03-14
Active, closed
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
NCT05262400Breast Cancer, Solid Tumors
DrugsPF-07104091·PF-07220060
Pfizer
Phase 1/2
235
Changchun, Shanghai, Chengdu, Tianjin, Hangzhou
2022-03-14
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
DrugsMosunetuzumab·Tocilizumab·Venetoclax·Rituximab
Hoffmann-La Roche
Phase 1
332
Beijing, Guangzhou, Nanchang, Tianjin
2022-03-07
Recruiting
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
NCT06690736CXCR4-related Disease, Tumor, Positron Emission Tomography, Metastasis
Tianjin Medical University
Not applicable
200
Hefei, Qingdao, Tianjin
2022-03-01
Recruiting
FAPI PET/CT in Various FAP-Related Disease Patients
NCT06688071FAP-related Disease, Tumor, Positron Emission Tomography, Metastasis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2022-03-01
Active, closed
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
NCT05247684Resectable Non-small Cell Lung Cancer
Akeso
Phase 2
90
Tianjin
2022-02-20
Active, closed
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537Age-Related Macular Degeneration
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
170
Harbin, Tianjin, Shanghai
2022-02-17
Recruiting
A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
NCT05641610Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
21
Tianjin
2022-02-16
Recruiting
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
NCT05214391Immune Thrombocytopenia, Treatment
DrugZanubrutinib
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2022-02-15
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
NCT05262491Gastrointestinal Tumor
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
96
Beijing, Nanchang, Jinan, Chengdu, Tianjin, Hangzhou
2022-02-14
Recruiting
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
NCT05199909Antiphospholipid Syndrome, Thrombocytopenia, Treatment
DrugZanubrutinib
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
10
Tianjin
2022-01-25
Active, closed
A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With Gastrointestinal Malignancies
NCT06997302Gastric (Stomach) Cancer, Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Not applicable
150
Tianjin
2022-01-01
Active, closed
Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug
NCT05203679Hemophilia B
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
32
Hefei, Beijing, Guangzhou, Shenzhen, Tangshan, Zhengzhou, Taiyuan, Tianjin
2021-12-30
Recruiting
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ascentage Pharma Group Inc.
Phase 2
75
Guangzhou, Haikou, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin, Hanzhou
2021-12-28
Recruiting
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479Myeloid Leukemia, Philadelphia Positive
Novartis Pharmaceuticals
Phase 1/2
34
Hangzhou, Beijing, Shanghai, Tianjin
2021-12-27
Active, closed
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA)
DrugRilzabrutinib
Sanofi
Phase 2
22
Beijing, Tianjin
2021-12-07
Recruiting
Diagnosis and Comprehensive Treatment of Mediastinal Interventional Technique
NCT06128681Mediastinal Diseases
Dan Liu
Observational
30
Tianjin
2021-12-01
Recruiting
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
NCT04807673Esophageal Squamous Cell Carcinoma
DrugsCisplatin·Pembrolizumab·Paclitaxel
Tianjin Medical University Cancer Institute and Hospital
Phase 3
342
Tianjin
2021-12-01
Recruiting
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
NCT05145127Hemophilia A, Hemophilia B
Pfizer
Phase 3
245
Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin, Beijing
2021-11-17
Active, closed
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04812925Primary Immune Thrombocytopenia
DrugEfgartigimod PH20
argenx
Phase 3
173
Beijing, Bengbu, Huizhou, Shenzhen, Tianjin, Wuhan, Wuxi, Zhengzhou
2021-11-17
Recruiting
Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
NCT06021678CD20-positive Non-Hodgkin Lymphoma
Guangzhou Excelmab Inc.
Phase 1/2
415
Zhengzhou, Jinan, Shanghai, Tianjin
2021-11-12
Recruiting
Cohort Study on Treatment of Cardiovascular Diseases With Traditional Chinese Medicine
NCT05309343Cardiovascular Diseases
Tianjin University of Traditional Chinese Medicine
Observational
20,000
Tianjin
2021-11-01
Recruiting
Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions-2
NCT05659160Stroke, Acute Ischemic, Endovascular Procedures, Large Vessel Occlusion
Tianjin Huanhu Hospital
Observational
5,000
Tianjin
2021-11-01
Active, closed
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097Relapsed or Refractory Follicular Lymphoma
DrugsMosunetuzumab·Lenalidomide·Rituximab
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Active, closed
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
NCT05030506Renal Cell Carcinoma
DrugsBelzutifan·Lenvatinib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1
45
Beijing, Guangzhou, Nanjing, Tianjin, Hangzhou
2021-10-13
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
645
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Active, closed
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
NCT04765059Non-small Cell Lung Cancer
DrugCarboplatin
AstraZeneca
Phase 3
98
Beijing, Ganzhou, Guangzhou, Jinan, Shenyang, Tianjin, Zhengzhou
2021-09-12
Recruiting
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
NCT04993885Immune Thrombocytopenia, Autoantibodies, Evan Syndrome, Connective Tissue Diseases
DrugAvatrombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
52
Tianjin
2021-09-01
Active, closed
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04747613Paroxysmal Nocturnal Hemoglobinuria
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
208
Beijing, Tianjin
2021-07-27
By invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
760
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Suzhou, Tianjin, Wenzhou
2021-07-27
Active, closed
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
NCT04944043Chronic Graft Versus Host Disease
DrugRovadicitinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
45
Hefei, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Tianjin
2021-06-25
Active, closed
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157Prostatic Neoplasms
DrugsARDT·68Ga-PSMA-11·AAA617
Novartis Pharmaceuticals
Phase 3
1,140
Nanjing, Xian, Chengdu, Beijing, Guangzhou, Shanghai, Tianjin
2021-06-09
Recruiting
National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
NCT06607289Hematological Malignancies
Institute of Hematology & Blood Diseases Hospital, China
Observational
1,000
Tianjin
2021-06-01
Recruiting
TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years
NCT04890041Primary Immune Thrombocytopenic Purpura
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
100
Tianjin
2021-05-30
Recruiting
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
NCT04686682NSCLC, SCLC, CRPC, ESCC
DrugJAB-8263
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
152
Tianjin
2021-05-07
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362Breast Cancer
DrugsTrastuzumab emtansine·Trastuzumab·Atezolizumab
Hoffmann-La Roche
Phase 3
1,188
Chengdu, Chongqing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Xi'an
2021-05-04
Recruiting
Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
NCT04908566Locally Advanced Gastric Adenocarcinoma
DrugsFolfirinox·Tislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
124
Tianjin
2021-05
Active, closed
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896Unresectable Hepatocellular Carcinoma
DrugsSorafenib·Atezolizumab·Lenvatinib
Hoffmann-La Roche
Phase 3
557
Changsha, Fuzhou, Guangzhou, Hefei, Nanjing, Shanghai, Shenyang, Tianjin
2021-04-26
Active, closed
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
NCT04683003Thrombotic Thrombocytopenic Purpura (TTP)
DrugTAK-755
Takeda
Phase 3
77
Beijing, Wuhan, Suzhou, Tianjin
2021-04-14
Active, closed
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
NCT04639180Hepatocellular Carcinoma (HCC)
DrugsRivoceranib·Apatinib·Tislelizumab
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
687
Chongqing, Nanjin, Guiyang, Shanghai, Tianjin
2021-04-01
Active, closed
Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer
NCT04836728Non-small Cell Lung Cancer Metastatic, First-line Treatment
Tianjin Medical University Cancer Institute and Hospital
Phase 2
156
Tianjin
2021-03-31
Recruiting
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
NCT05035147Pancreatic Cancer
DrugAlbumin-Bound Paclitaxel
Tianjin Medical University Cancer Institute and Hospital
Phase 4
934
Tianjin
2021-03-25
Active, closed
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition
NCT04654468Paroxysmal Nocturnal Hemoglobinuria
DrugCrovalimab
Hoffmann-La Roche
Phase 3
51
Chengdu, Guangzhou, Tianjin, Wuhan
2021-03-17
Recruiting
Gene Therapy for Chinese Hemophilia A
NCT04728841Hemophilia A, Gene Therapy
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
12
Tianjin
2021-03-04
Recruiting
China Monogenic Diabetes Registry
NCT07492004Neonatal Diabetes, Monogenic Diabetes, Maturity Onset Diabetes of the Young
Tianjin Medical University General Hospital
Observational
5,000
Tianjin
2021-02-28
Active, closed
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638Diffuse Large B-cell Lymphoma
DrugsRituxumab·Glofitamab·Tocilizumab·Obinutuzumab
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552Hematological Malignancies
DrugTalquetamab
Janssen Research & Development, LLC
Phase 2
510
Beijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Xi'an
2021-02-01
Recruiting
Clinical Treatment of Transcranial Direct Current Stimulation in Older Adolescents With Amblyopia
NCT06760910Amblyopia
Tianjin Eye Hospital
Not applicable
40
Tianjin
2021-01-30
Active, closed
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845Solid Tumors
DrugsBelvarafenib·Ipatasertib·Pralsetinib·Divarasib
Hoffmann-La Roche
Phase 2
920
Beijing, Chengdu, Shanghai, Tianjin, Xi'an
2021-01-18
Active, closed
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
NCT04718883Mantle Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
59
Beijing, Fuzhou, Guanzhou, Zhengzhou, Nanjing, Shanghai, Tianjin, Hangzhou
2021-01-13
Recruiting
A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer
NCT04843215Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Not applicable
950
Tianjin
2021-01-01
Recruiting
Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
NCT04688736Allergic Transfusion Reaction
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
6,642
Hefei, Zhoukou, Tai’an, Tianjin
2021-01-01
Recruiting
Eltrombopag for Chemotherapy-induced Thrombocytopenia
NCT04600960Chemotherapy-induced Thrombocytopenia, Eltrombopag
DrugEltrombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2020-12-31
Active, closed
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
NCT04562766Immune Thrombocytopenia
DrugRilzabrutinib
Principia Biopharma, a Sanofi Company
Phase 3
232
Wuhan, Shenyang, Xi'an, Jinan, Tianjin, Kunming, Hangzhou, Hefei
2020-12-14
Recruiting
Artificial Intelligence for Screening of Multiple Corneal Diseases
NCT06211218Deep Learning, Corneal Disease, Screening
Tianjin Eye Hospital
Observational
3,000
Tianjin
2020-12-06
Recruiting
National Longitudinal Cohort of Hematological Diseases
NCT04645199Multiple Myeloma, Acute Myeloid Leukemia, Hemophilia, Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Observational
2,300
Tianjin
2020-12-01
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Fulvestrant
Hoffmann-La Roche
Phase 2
303
Changchun, Guangzhou, Linyi, Nanchang, Shanghai, Tianjin, Wuhan, Xi'an
2020-11-27
Active, closed
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT04606433Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Recruiting
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
NCT06487663Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable, Liver Metastases, Liver Malignant Tumors
Tianjin Medical University Cancer Institute and Hospital
Not applicable
40
Tianjin
2020-10-27
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Beijing, Guiyang, Hunan, Jinan, Shanghai, Suzhou, Tianjin, Xi'an
2020-10-15
Active, closed
Efficacy and Influencing Factors of Repeated Low-level Red-light in Myopia
NCT07104513Myopia
Ruihua Wei
Observational
3,000
Tianjin
2020-09-28
Active, closed
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098Hematological Malignancies
DrugTeclistamab
Janssen Research & Development, LLC
Phase 2
194
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Xi'an
2020-09-17
Active, closed
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
DrugsPF-07104091·Palbociclib·Letrozole·Fulvestrant
Pfizer
Phase 2
157
Shanghai, Tianjin
2020-09-16
Active, closed
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
NCT05395533CD20-positive B-cell Non-Hodgkin Lymphoma
DrugTRS005
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1
147
Beijing, Guangzhou, Zhengzhou, Suzhou, Tianjin
2020-09-08
Recruiting
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
NCT06690970PSMA-related Disease, Prostate Cancer, Positron Emission Tomography, Metastasis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2020-09-01
Recruiting
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
NCT04518475Primary Immune Thrombocytopenia (ITP)
DrugEltrombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
224
Tianjin
2020-08-10
Recruiting
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
NCT05551507Platinum-resistant Ovarian Cancer
DrugIN10018
InxMed (Shanghai) Co., Ltd.
Phase 1/2
150
Anyang, Beijing, Changsha, Fuzhou, Hangzhou, Tianjin, Zhengzhou
2020-07-27
Active, closed
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
NCT04191304Hypereosinophilic Syndrome
DrugBenralizumab
AstraZeneca
Phase 3
134
Chengdu, Shanghai, Tianjin, Xiamen, Zhengzhou
2020-07-20
Active, closed
Linerixibat Long-term Safety, and Tolerability Study
NCT04167358Cholestasis
GlaxoSmithKline
Phase 3
242
Beijing, Changchun, Chongqing, Guangzhou, Nanchang, Nanjing, Shanghai, Tianjin
2020-07-14
Recruiting
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
NCT04440267Acute Leukemia of Ambiguous Lineage
DrugsMercaptopurine·Daunorubicin·Methotrexate·Vincristine
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2020-07-08
Active, closed
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945Pulmonary Arterial Hypertension
DrugMacitentan
Actelion
Phase 3
935
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Shanghai, Shenyang, Tianjin
2020-06-30
Active, closed
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
NCT04270409Plasma Cell Myeloma
DrugsIsatuximab SAR650984·Montelukast·Diphenhydramine·Acetaminophen
Sanofi
Phase 3
337
Hangzhou, Nanchang, Shanghai, Shenyang, Tianjin
2020-06-16
Active, closed
Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia
NCT04415008CEBPA Double Mutation, Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
61
Tianjin
2020-06-01
By invitation
Environmental Factors and Myopia Prevalence Among Uyghur Students in Remote China
NCT07119723Myopia, Environment
Tianjin Medical University Eye Hospital
Observational
100,000
Tianjin
2020-06-01
Active, closed
The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
NCT04398459Refractory/Relapsed Autoimmune Hemolytic Anemia
DrugIbrutinib
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
18
Zhoukou, Tai’an, Tianjin
2020-05-01
Active, closed
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210Multiple Myeloma
DrugsBelantamab mafodotin·Dexamethasone
GlaxoSmithKline
Phase 3
325
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Tianjin
2020-04-02
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
NCT04280081Solid Tumor, Medullary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 2
77
Beijing, Guangzhou, Changsha, Changchun, Jinan, Shanghai, Tianjin, Hangzhou
2020-03-16
Active, closed
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
NCT04024696Non Hodgkin Lymphoma
DrugAbexinostat
Xynomic Pharmaceuticals, Inc.
Phase 1/2
12
Beijing, Hangzhou, Tianjin, Xuzhou
2020-01-08
Active, closed
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105B-cell Non-Hodgkin Lymphoma (B-NHL)
DrugOdronextamab
Regeneron Pharmaceuticals
Phase 2
515
Beijing, Tianjin, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Suzhou
2019-11-13
Recruiting
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
NCT06550713Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
DrugAzacitidine
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
100
Beijing, Shijiazhuang, Harbin, Shanghai, Chengdu, Tianjin
2019-10-22
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Tianjin, Xi'an, Hangzhou
2019-10-03
Active, closed
Extension Study of Hetrombopag in Severe Aplastic Anemia
NCT04961710Treatment-naive Severe Aplastic Anemia
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
157
Tianjin
2019-09-19
Active, closed
Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System
NCT04023370Iliac Artery Stenosis
Bentley InnoMed GmbH
Not applicable
182
Beijing, Shanghai, Suzhou, Tianjin, Wuhan, Zhejiang
2019-09-19
Recruiting
Interstitial Lung Disease and Obstructive Sleep Apnea
NCT05838183ILD OSA
Dan Liu
Observational
70
Tianjin
2019-09-01
Recruiting
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
NCT04135664Esophageal Cancer
Shanghai Chest Hospital
Phase 3
176
Nanchang, Shanghai, Tianjin
2019-09-01
Rows per page Showing 801–900 of 940
Previous 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin?page=9

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 940 of those studies with a site in Tianjin.

How many clinical trials are recruiting in Tianjin?

601 of the 940 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 153 have not yet opened recruitment, 162 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.